In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

Immuno-Oncology Industry News

Date Title
22/01/2016

Novel Approaches Explored in HER2-Positive Gastric Cancer - Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center

12/11/2015

Cancer Immunotherapy: The Cutting Edge Gets Sharper  - Scientific American October 2015

03/11/2015

Axel Hoos, GSK interviewed at BIO 2015: Focusing on immuno-oncology and cancer epigenetics

31/07/2015

Cancer vaccines field to see sizable growth, report says

19/06/2015

GSK takes another big swing at cancer drug R&D - article featuring Dr Axel Hoos, NED at Imugene

16/04/2015

The Immune System Fights Back with CART

27/02/2015

Yes to Flexus: The Science And Strategy Behind A Huge Biotech Return

25/12/2014

Fierce Biotech - Bristol-Myers' pioneering PD-1 drug Opdivo OK'd by FDA for melanoma

09/12/2014

Wall Street Journal, Ron Winslow - How the Promise of Immunotherapy is Transforming Oncology

20/11/2014

The Australian - Biomedical stocks racing to solve a $40bn problem

18/11/2014

Pfizer ($PFE) is determined to be a major player in the fast-emerging field of immuno-oncology, and the pharma giant is paying handsomely to buy its way into an anti-PD-L1 program now underway at Merck KGaA. In a deal announced Monday Pfizer outlined plans to pay a whopping $850 million upfront and up to $2 billion in milestones for the right to co-develop and co-market MSB0010718C and any other IO drugs they put in the pipeline.  Click here to view.

 
 
 

© Imugene 2017. All rights reserved. ABN 99 009 179 551